Amneal Pharmaceuticals (AMRX) Restructuring Costs (2017 - 2026)

Amneal Pharmaceuticals' Restructuring Costs history runs 10 years deep, the most recent figure standing at $650000.0 for Q1 2026.

• In Q1 2026, Restructuring Costs changed N/A year-over-year to $650000.0; the TTM figure through Mar 2026 stood at $4.3 million (up 384.41% YoY), while the FY2025 annual figure was $4.2 million, up 78.68% from the prior year.
• Restructuring Costs was $650000.0 for Q1 2026 at Amneal Pharmaceuticals, down from $2.5 million in the prior quarter.
• In the past five years, Restructuring Costs ranged from a high of $2.5 million in Q4 2025 to a low of -$612000.0 in Q4 2022.
• Historically, Restructuring Costs has averaged $606066.7 across 5 years, with a median of $510000.0 in 2023.
• The sharpest annual moves came in 2022 and 2025: Restructuring Costs sank 108.37% in 2022, then soared 401.01% in 2025.
• A 5-year view of Restructuring Costs shows it stood at -$612000.0 in 2022, then soared by 118.63% to $114000.0 in 2023, then jumped by 332.46% to $493000.0 in 2024, then jumped by 401.01% to $2.5 million in 2025, then plunged by 73.68% to $650000.0 in 2026.
• The last three Restructuring Costs figures came in at $650000.0 (Q1 2026), $2.5 million (Q4 2025), and $143000.0 (Q3 2025), per Business Quant data.